Follow-up findings in young females with XXXX papanicolaou test results.

@entity5 @entity189 @entity1082 @entity2784 @entity420 @entity3146
CONTEXT: New guidelines discourage cervical screening and procedures in young females, given available @entity1082 vaccines, concerns regarding procedure-associated harms, and the rarity of @entity5 . OBJECTIVE: To analyze histopathologic follow-up data on a large number of young females with @entity2784 ( @entity2784 ) Papanicolaou (Pap) test results. DESIGN: Hospital records were searched for @entity2784 Pap test results in females 20 years or younger between January 2002 and December 2007. Histopathologic and Pap test follow-up, age group variations, and impact of Pap test transformation zone/endocervical sampling were analyzed. RESULTS: Four hundred seventy-four females aged 20 years or younger had @entity2784 Pap test results during the study period. Three hundred thirty-five young females with at least one cervical biopsy were included. The average age was 18.6 years (range, 13-20 years). The average follow-up period was 24 months (range, 0.1-75 months), with a median of 22 months. Histopathologic detection rates were 44.2% for @entity3146 ( @entity3146 ) 2/3 and 47.8% for @entity3146 1. The average period between the @entity2784 Pap test result and an initial diagnosis of @entity3146 2/3 was 5 months (range, 0.1-62 months), with a median of 2 months. Neither @entity189 nor @entity420 in situ was identified. Presence or absence of a transformation zone/endocervical sample did not significantly impact @entity3146 2/3 risk (44.5% versus 38.9%, P = .64). CONCLUSIONS: Histopathologic @entity3146 2/3 was documented in 148 of 335 (44%) of biopsied young females with @entity2784 Pap results, likely reflecting both the reported high likelihood of @entity2784 regression in younger females and the challenge of colposcopic sampling of relatively short-lived smaller @entity3146 2/3 lesions. Although no cases of @entity189 were identified in this study, updated guidelines pose new risks for maturing females with undetected cervical precancer.
